Biomarkers of pulmonary fibrosis in COVID-19 and postcovid syndrome
COVID-19 can occur in the form of an acute respiratory viral infection of a mild course, or in a severe form. Both effective treatments for the acute phase of the disease and the clinical and functional long-term consequences of COVID-19, which include the complexity of symptoms and organ damage ref...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Open Systems Publication
2022-10-01
|
| Series: | Лечащий Врач |
| Subjects: | |
| Online Access: | https://journal.lvrach.ru/jour/article/view/966 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849404168035368960 |
|---|---|
| author | M. K. Kurbanaliev T. A. Potselueva E. A. Lyakh D. A. Shtonda I. V. Rodionova V. V. Skvortsov |
| author_facet | M. K. Kurbanaliev T. A. Potselueva E. A. Lyakh D. A. Shtonda I. V. Rodionova V. V. Skvortsov |
| author_sort | M. K. Kurbanaliev |
| collection | DOAJ |
| description | COVID-19 can occur in the form of an acute respiratory viral infection of a mild course, or in a severe form. Both effective treatments for the acute phase of the disease and the clinical and functional long-term consequences of COVID-19, which include the complexity of symptoms and organ damage referred to as «long-term COVID» or «post-acute COVID-19 syndrome», are attracting interest in the medical community. The term «post-acute COVID-19 syndrome» has been proposed to refer to symptoms and/or abnormalities that are not related to another cause, persist or are present after four weeks of the diagnosis of the disease. One of the key components of the post-acute COVID-19 syndrome, which can lead to serious complications of the clinical course in patients, is considered to be pulmonary fibrosis, which is a pathological outcome of chronic and acute interstitial lung disease. COVID-19 itself is relatively new disease, which makes it difficult to study the course of the pathological process. To analyze the pathogenesis, multiple studies were conducted on patients who had been ill with various forms of COVID-19. After the disease, the body can begin both the normal process of regeneration of lung tissue and its distortion, leading to severe complications and long-term restoration of normal functioning of the whole organism. In pulmonary fibrosis, the number of deaths is much higher, which is why biomarkers of this outcome have been developed in order to reduce the number of deaths from the COVID-19 complication. The review is devoted to the epidemiology, pathogenesis, histopathology of pathological flora in COVID-19, postcovid syndrome and biomarkers that can identify patients with an increased likelihood of developing the disease. The purpose of this review is to describe various pathogenic hypotheses that have been formulated in order to explain the development of pulmonary fibrosis, the study of acute phases associated with biomarkers that could suggest the onset of fibrotic lung lesions. |
| format | Article |
| id | doaj-art-c3af01f9582f4303ba79cf5fb86f5cf1 |
| institution | Kabale University |
| issn | 1560-5175 2687-1181 |
| language | Russian |
| publishDate | 2022-10-01 |
| publisher | Open Systems Publication |
| record_format | Article |
| series | Лечащий Врач |
| spelling | doaj-art-c3af01f9582f4303ba79cf5fb86f5cf12025-08-20T03:37:05ZrusOpen Systems PublicationЛечащий Врач1560-51752687-11812022-10-01110162010.51793/OS.2022.25.10.003961Biomarkers of pulmonary fibrosis in COVID-19 and postcovid syndromeM. K. Kurbanaliev0T. A. Potselueva1E. A. Lyakh2D. A. Shtonda3I. V. Rodionova4V. V. Skvortsov5Federal State Budgetary Educational Institution of Higher Education Volgograd State Medical University of the Ministry of Health of the Russian FederationFederal State Budgetary Educational Institution of Higher Education Volgograd State Medical University of the Ministry of Health of the Russian FederationFederal State Budgetary Educational Institution of Higher Education Volgograd State Medical University of the Ministry of Health of the Russian FederationFederal State Budgetary Educational Institution of Higher Education Volgograd State Medical University of the Ministry of Health of the Russian Federation; State Healthcare Institution Clinical Emergency Hospital No. 15Federal State Budgetary Educational Institution of Higher Education Volgograd State Medical University of the Ministry of Health of the Russian FederationFederal State Budgetary Educational Institution of Higher Education Volgograd State Medical University of the Ministry of Health of the Russian FederationCOVID-19 can occur in the form of an acute respiratory viral infection of a mild course, or in a severe form. Both effective treatments for the acute phase of the disease and the clinical and functional long-term consequences of COVID-19, which include the complexity of symptoms and organ damage referred to as «long-term COVID» or «post-acute COVID-19 syndrome», are attracting interest in the medical community. The term «post-acute COVID-19 syndrome» has been proposed to refer to symptoms and/or abnormalities that are not related to another cause, persist or are present after four weeks of the diagnosis of the disease. One of the key components of the post-acute COVID-19 syndrome, which can lead to serious complications of the clinical course in patients, is considered to be pulmonary fibrosis, which is a pathological outcome of chronic and acute interstitial lung disease. COVID-19 itself is relatively new disease, which makes it difficult to study the course of the pathological process. To analyze the pathogenesis, multiple studies were conducted on patients who had been ill with various forms of COVID-19. After the disease, the body can begin both the normal process of regeneration of lung tissue and its distortion, leading to severe complications and long-term restoration of normal functioning of the whole organism. In pulmonary fibrosis, the number of deaths is much higher, which is why biomarkers of this outcome have been developed in order to reduce the number of deaths from the COVID-19 complication. The review is devoted to the epidemiology, pathogenesis, histopathology of pathological flora in COVID-19, postcovid syndrome and biomarkers that can identify patients with an increased likelihood of developing the disease. The purpose of this review is to describe various pathogenic hypotheses that have been formulated in order to explain the development of pulmonary fibrosis, the study of acute phases associated with biomarkers that could suggest the onset of fibrotic lung lesions.https://journal.lvrach.ru/jour/article/view/966pulmonary fibrosishistopathologyepidemiologypathogenetic mechanismsconsequencesbiomarkers |
| spellingShingle | M. K. Kurbanaliev T. A. Potselueva E. A. Lyakh D. A. Shtonda I. V. Rodionova V. V. Skvortsov Biomarkers of pulmonary fibrosis in COVID-19 and postcovid syndrome Лечащий Врач pulmonary fibrosis histopathology epidemiology pathogenetic mechanisms consequences biomarkers |
| title | Biomarkers of pulmonary fibrosis in COVID-19 and postcovid syndrome |
| title_full | Biomarkers of pulmonary fibrosis in COVID-19 and postcovid syndrome |
| title_fullStr | Biomarkers of pulmonary fibrosis in COVID-19 and postcovid syndrome |
| title_full_unstemmed | Biomarkers of pulmonary fibrosis in COVID-19 and postcovid syndrome |
| title_short | Biomarkers of pulmonary fibrosis in COVID-19 and postcovid syndrome |
| title_sort | biomarkers of pulmonary fibrosis in covid 19 and postcovid syndrome |
| topic | pulmonary fibrosis histopathology epidemiology pathogenetic mechanisms consequences biomarkers |
| url | https://journal.lvrach.ru/jour/article/view/966 |
| work_keys_str_mv | AT mkkurbanaliev biomarkersofpulmonaryfibrosisincovid19andpostcovidsyndrome AT tapotselueva biomarkersofpulmonaryfibrosisincovid19andpostcovidsyndrome AT ealyakh biomarkersofpulmonaryfibrosisincovid19andpostcovidsyndrome AT dashtonda biomarkersofpulmonaryfibrosisincovid19andpostcovidsyndrome AT ivrodionova biomarkersofpulmonaryfibrosisincovid19andpostcovidsyndrome AT vvskvortsov biomarkersofpulmonaryfibrosisincovid19andpostcovidsyndrome |